bearish
Celltrion's FDA CRL Issue Summary
264 Views09 Apr 2018 05:43
Celltrion Inc (068270 KS) is still right at the center of attention among Korean stock short sellers despite its KOSPI move.What is more critical...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much30 Aug 2018
- Celltrion (068270): Time Is Not Right for Short Sellers Yet14 Aug 2018
- A Further Study on Celltrion-Celltrion Healthcare Market Cap Spread Movement28 May 2018
- Celltrion Holdings' ₩200bil CB with Celltrion Healthcare as Pledged Article - Questions to Ask11 Mar 2018
- ION's Celltrion Block Deals - Summary & Impacts07 Mar 2018
- Short Selling Viability Assessment on Celltrion After KOSPI 200 Inclusion03 Mar 2018
x